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Abstract

Cell loss immediately adjacent to an intracerebral hemorrhage may be mediated in part by the
toxicities of extracellular hemoglobin (Hb) and thrombin. However, at low concentrations, these
proteins induce tolerance to hemin and iron that may limit further peri-hematomal injury as
erythrocyte lysis progresses. The mechanisms mediating these preconditioning effects have not
been completely defined, but increased expression of both heme oxygenase (HO)-1 and iron
binding proteins likely contributes. In the present study, we hypothesized that iron chelator
therapy would attenuate this protective response. Pretreatment of cortical glial cultures (> 90%
GFAP+) with 3 µM methemoglobin (metHb) or 5 units/ml thrombin for 24h was nontoxic per se,
and increased HO-1 and ferritin expression. When challenged with a toxic concentration of
hemin, the increase in cellular redox-active iron was attenuated in preconditioned cultures and
cell survival was increased. However, if cultures were pretreated with metHb or thrombin plus
deferoxamine or 2, 2’-bipyridyl, ferritin induction was prevented and cellular redox-active iron
increased with hemin treatment.

Preconditioning-mediated cytoprotection was consistently

reduced by deferoxamine, while 2,2’bipyridyl had a variable effect.

Neither chelator altered

HO-1 expression. A cytoprotective response was preserved when chelator therapy was limited to
11 hours of the 24h preconditioning interval. These results suggest a potentially deleterious
effect of continuous iron chelator therapy after ICH. Intermittent therapy may remove perihematomal iron without negating the benefits of exposure to low concentrations of Hb or
thrombin.
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Introduction
A considerable body of experimental evidence suggests that release of thrombin and
hemoglobin (Hb) from an intracerebral hematoma contributes to cell loss in adjacent tissue.
Thrombin, via its interaction with protease-activated receptors, may increase perihematomal
injury by activating matrix metalloproteinase-9, NADPH oxidase, and complement, upregulating
NMDA receptors, and increasing neuronal cell cycle reentry [1-3]. Hb toxicity is mediated by
release of its heme moieties after autoxidation to methemoglobin, resulting in hemin or ironcatalyzed free radical reactions [4]. The hypothesis that nonheme iron toxicity participates in the
pathogenesis of intracerebral hemorrhage (ICH) is supported by observations that iron chelators
are protective when administered to rodents or piglets as bolus injections [5-7], and is now being
tested in clinical trials [8].
The protective effects of Hb and thrombin have been less-intensively investigated, but
may be critical in limiting iron-mediated perihematomal injury as erythrocyte lysis progresses.
Exposure to nontoxic concentrations of either protein induces robust tolerance to hemin or ironmediated oxidative stress [9-11]. Although the mechanisms mediating these phenomena have
not been defined, both thrombin and Hb increase expression of heme oxygenase (HO)-1 and iron
binding proteins [9, 10, 12, 11], thereby facilitating heme breakdown and iron sequestration.
The primary intracellular defense against redox-active iron is provided by ferritin, a 24mer protein that can sequester and detoxify over 4000 iron atoms in its mineral core [13]. Cell
ferritin synthesis is inhibited under physiologic conditions by the mRNA binding activities of
iron regulatory protein (IRP)-1 and IRP-2.

As cell iron levels increase, IRP’s are rapidly

degraded and binding activity is decreased, enabling translation. We recently reported that both
deferoxamine (DFO) and 2,2'-bipyridyl enhance iron export and inhibit its re-uptake in cultured
neural cells [14], significantly decreasing nonheme iron. Since ferritin expression is a direct
function of cell iron content, we hypothesized that chelators would prevent the increase in
ferritin produced by Hb or thrombin preconditioning, and eliminate its subsequent protective
effect. Given the potential relevance to iron chelator therapy for ICH, this hypothesis was tested
in cultured glial cells, which are key drivers of preconditioning responses in the CNS [15].
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Materials and Methods
Primary glial cultures
Cortical glial cultures (> 90% GFAP +) were prepared from 2-3 day old C57BL/6 X 129/Sv
mice that were bred in our animal facility, following a protocol that was approved by the local
Institutional Animal Care and Use Committee and previously described in detail [16].
Approximately two-thirds of the culture medium was replaced at 5-6 days in vitro and then twice
weekly, using growth medium containing minimal essential medium (MEM), 23 mM glucose, 2
mM glutamine, and 10% equine serum (Hyclone, Logan, UT, USA).

Cytotoxicity experiments
Confluent cultures were washed free of growth medium and were then exposed for 24 h to 3 µM
bovine oxidized hemoglobin (methemoglobin, metHb) or 5 units/ml thrombin, alone or with 100
µM of either deferoxamine or 2,2’-bipyridyl (all reagents purchased from Sigma-Aldrich, St.
Louis, MO).

Preconditioning concentrations of metHb and thrombin were based on prior

published studies [10, 17] and preliminary experiments that demonstrated efficacy in this cell
culture model.

Control cultures were incubated with experimental medium only, which

consisted of Minimal Essential Medium (Gibco, Life Technologies, Grand Island, NY, USA)
containing 10 mM glucose (MEM10). At the end of the preconditioning interval, cultures were
washed with MEM10 (0.75 ml X 2) and were then treated with 30 µM hemin (Frontier
Scientific, Logan, UT, USA) in MEM10, without any chelators. In all experiments, cell injury
was estimated by inspecting cultures under phase contrast optics.

Cell viability was then

quantified using the lactate dehydrogenase (LDH) release assay, as previously described [18].
The low mean LDH activity in sister cultures subjected to medium exchanges only was
subtracted from all values to obtain the LDH activity due to hemin toxicity, following the
protocol of Koh and Choi [19]. Prior studies have demonstrated that cell vulnerability to hemin
is consistent in cultures prepared from the same plating but varies somewhat from plating to
plating, particularly if different serum samples are used. All direct comparisons were therefore
made using sister cultures prepared with the same serum sample.
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Immunoblotting
Cells were collected in 100 µl ice-cold lysis buffer (210 mM mannitol, 70 mM sucrose, 5 mM
HEPES, 1 mM EDTA, 0.1 % sodium dodecyl sulfate, 0.1 % Triton X-100). After sonication and
centrifugation, the protein concentration of the supernatant was quantified by the BCA method
(Thermo Fisher Scientific, Inc., Rockford, IL, USA). Protein separation and transfer followed
previously described protocols [20]. Membranes were incubated overnight at 4oC with rabbit
anti-HO-1 (1:5000, Enzo Life Sciences, Inc, Farmingdale, NY, USA), rabbit anti-horse spleen
ferritin (1:250, Sigma-Aldrich, St. Louis, MO, USA), or rabbit anti-actin (1:1000, SigmaAldrich) as a gel-loading control, followed by HRP-conjugated secondary antibody (1:3500,
Thermo Fisher) for 1h at room temperature.

Immunoreactive proteins were visualized using

Super Signal West Femto Reagent (Thermo Fisher Scientific) and Kodak Gel Logic 2200.

Cell labile iron assay
Changes in cytosolic redox active iron (the labile iron pool) were detected by quantifying calcein
fluorescence quenching in hemin-treated cultures, as previously described [16, 21]. Cultures
were pretreated with 3 µM metHb or 5 units/ml thrombin for 24 h, alone or with chelators,
following the protocol described in the cytotoxicity experiments section.

Since membrane

integrity is essential for these experiments, hemin exposure was conducted in 3.3% equine
serum, which attenuates the toxicity of hemin, and was terminated by medium exchange at three
hours. After treatment with 0.1 M calcein-AM for 15 min, cultures were examined using an
inverted microscope with epifluorescence attachment and an FITC filter. Digital 100X images in
the center of each well were captured and analyzed using iVision‐MacTM software (BioVision
Technologies, Exton, PA).

Fluorescence of hemin-treated cultures was expressed as a

percentage of that in sister cultures from the same plating subjected to medium exchanges only.

Data analyses
All data were analyzed using one-way analysis of variance (ANOVA) followed by the
Bonferroni multiple comparisons post hoc test, using GraphPad InStat software (San Diego,
CA).
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Results
Iron chelators reduce ferritin induction by metHb and thrombin. MetHb is the predominant
extracellular Hb in an intracerebral hematoma [22], and was therefore used as a preconditioning
stimulus rather than reduced Hb. Consistent with prior observations [10], no cell death was
observed in glial cultures treated for 24 hours with 3 µM metHb [10]. Compared with control
cultures subjected to medium exchanges only, HO-1 expression increased 5.5-fold after metHb
treatment, while ferritin increased fourfold (Fig. 1). Concomitant treatment with either DFO and
2,2'-bipyridyl (100 µM) attenuated ferritin induction, but had no effect on HO-1. Thrombin (5
units/ml) also increased expression of HO-1 and ferritin, but less robustly than metHb (Fig. 2);
the chelator effect was similar to that observed in metHb-treated cultures.
MetHb or thrombin preconditioning reduces cell labile iron after hemin treatment. Since each
ferritin molecule can sequester over 4000 ferric ions in it mineral core [13], we hypothesized that
the increase in the labile iron pool that we have previously observed in these cultures after hemin
treatment [16] would be reduced by metHb or thrombin preconditioning. Cytosolic labile iron,
as detected by calcein fluorescence quenching [21], was significantly decreased in cultures
pretreated with 3 µM metHb followed by 30 µM hemin, compared with control cultures
pretreated with MEM10 medium alone before hemin exposure (Fig. 3a-i). However, this effect
was completely lost when the preconditioning stimulus was delivered with either DFO or 2,2'bipyridyl (100 µM), followed by hemin treatment without chelators. Thrombin (5 units/ml)
pretreatment also attenuated the rise in labile iron after hemin treatment, and adding chelators to
the preconditioning medium also negated its effect (Fig. 3j).
Protective effect of preconditioning is reduced by iron chelators. In control cultures pretreated
with MEM10 medium only, exposure to 30 µM hemin for 24 hours consistently resulted in
death, as measured by LDH release assay, of over 60% of cells (Fig. 4). However, injury
progression varied somewhat from culture to culture, resulting in cell loss at 8 hours ranging
from 31±2% to 60±4%.

Both metHb and thrombin preconditioning provided significant

protection at both time points, although the effect was more robust with the former. When the
preconditioning stimulus was delivered with 100 µM DFO, followed by washout and treatment
with hemin alone, the protective benefit was consistently lost. 2.2’-bipyridyl (100 µM) had a
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more variable effect.

In cultures pretreated with metHb, it negated preconditioning

cytoprotection, consistent with DFO results. However, in thrombin preconditioning experiments,
the presence of 2.2’-bipyridyl in the preconditioning medium provided additional protection to
cultures treated with hemin for 8 hours, but not 24 hours.
Ferritin is rapidly induced in glial cells [10], so we hypothesized that decreasing the
duration of chelator therapy would preserve the cytoprotective effect of metHb and thrombin
preconditioning. Additional cultures were therefore pretreated for 24 hours with either protein,
but with DFO for only 11 hours. The latter interval was chosen since it approximates the longest
duration of serum DFO levels in a 24 h period attained in a recent ICH clinical trial, which was
estimated from the infusion interval of 8.3 hours and published pharmacokinetic data [8, 23].
This shorter duration of DFO treatment had no effect on the protection provided by either
preconditioning stimulus (Fig. 5).

Discussion
These results demonstrate that iron chelators antagonize the protective effect of metHb or
thrombin preconditioning in glial cultures containing predominantly astrocytes.

Both

preconditioning stimuli increased expression of HO-1 and ferritin, which have previously been
reported to protect astrocytes from hemin toxicity [10, 24, 16].

However, when the

preconditioning medium also contained DFO or 2,2’-bipyridyl, ferritin induction was prevented,
without change in HO-1 expression. This resulted in loss of iron homeostasis when cells were
subsequently challenged with a toxic concentration of hemin in the absence of any chelators.
Preconditioning with DFO also increased cell death due to hemin exposure, while lipophilic 2,2bipyridyl had a more variable effect. These observations suggest a potentially deleterious impact
of iron chelators after CNS hemorrhage that should be further investigated in ICH models in
vivo. To the extent that low concentrations of endogenous metHb and thrombin increase cellular
resistance to hemin and iron in perihematomal tissue, this protective response may be weakened
by continuous chelator therapy. These cells may then be more vulnerable to injury as hemin and
iron levels increase, particularly if chelator therapy is discontinued prior to hematoma resolution.
7

The present results also suggest that chelator therapy may not be compatible with
preconditioning or postconditioning therapies involving the administration of exogenous
thrombin or hemoproteins.
Considerable experimental evidence supports the hypothesis that DFO is beneficial after
CNS hemorrhage [6, 5], although negative results have also been reported [25]. In these studies,
DFO was administered by bolus intraperitoneal (i.p.) or intramuscular (i.m.) injection every 12
hours for 3-7 days, with therapy continuing until the animal was killed. When used clinically,
DFO is always administered by slow intravenous (i.v.) or subcutaneous (s.c) infusion over
several hours, due to its short half-life (0.3-0.56 h [23]) and early reports of severe hypotension
after bolus injections to treat children with iron poisoning [26]. Although data regarding the
pharmacokinetics of DFO when administered by bolus i.p. or i.m. injections are not available, it
is very likely that the dosing regimens used in animal studies produce therapeutic levels
intermittently and for less than half of a 24 h interval. In the present study, the beneficial effects
of methemoglobin and thrombin were fully maintained when chelators were present for only 11
h of the 24 h preconditioning interval, suggesting that intermittent therapy may be preferable if a
postconditioning stimulus is in fact beneficial. However, a hematoma will continuously produce
iron, and the quantity produced may overwhelm any benefit of thrombin or methemoglobin
postconditioning. It is therefore also possible that continuous chelator therapy is preferable. The
latter treatment regimen has never been tested in an animal model, and should be further
explored.
These results provide additional evidence that hemin toxicity in this culture system is
mediated in part by chelatable iron.

We have previously reported that heme oxygenase

expression is a critical determinant of the vulnerability of glial cells to hemin [27, 28, 24]. In
those studies, expression of HO-1 or HO-2 was modified by gene transfer or knockout, without
any intervention to reduce ferritin upregulation in response to iron release. Cell death was
observed to be an inverse function of HO expression and activity under those experimental
conditions. In contrast, in the present study, addition of an iron chelator to the preconditioning
medium had no impact whatsoever on HO-1 induction, but prevented ferritin upregulation and
antagonized the cytoprotective effect of preconditioning in most experiments. Taken together,
these observations demonstrate that HO activity is not sufficient per se to protect glial cells from
hemin. Sufficient ferritin is also needed to sequester redox active iron that is released with
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hemin breakdown. These results are in agreement with observations by Balla et al. in aortic
endothelial cells [9], and our prior studies using combined pretreatment with HO-1 and ferritin
inducers in this model [10].
The beneficial effect of thrombin preconditioning on cell iron homeostasis during
subsequent hemin exposure was antagonized by both DFO and 2,2’-bipyridyl. However, while
DFO consistently had a negative impact on cell survival, as did 2,2-bipyridyl in methemoglobin
preconditioning experiments, pretreatment with 2,2-bipyridyl plus thrombin was moderately
more protective than thrombin alone. These results suggest that 2,2-bipyridyl plus thrombin
activates a protective signaling cascade that is not dependent on ferritin expression and
chelatable iron levels, and that is not activated by 2,2-bipyridyl plus metHb or by DFO plus
either thrombin or metHb. The molecular basis for this cytoprotective effect is undefined and
seems a worthy subject for future investigation. Compared with DFO, 2,2-bipyridyl is more
accessible to cells due to its lipophilicity [29, 30], and rapidly induces HIF-1α-dependent genes
via prolyl hydroxylase inhibition [31]. Since thrombin preconditioning also increases expression
of HIF-1α target genes [11], combined treatment may have an additive or synergistic effect. It is
noteworthy that 2,2-bipyridyl preconditioning was protective in a photothrombotic model of
cortical ischemia via an undefined mechanism that was independent of iron chelation, reactive
oxygen species formation and HO-1 expression [32]
The component of perihematomal injury that is mediated by heme is delayed until 3 days
after hemorrhage in rodent models [33], which likely reflects the interval required for widespread
erythrocyte lysis. It therefore may be highly amenable to postconditioning therapies with low
concentrations of hemoglobin or thrombin. The present results suggest that any postconditioning
benefit may be negated by concomitant treatment with DFO. If these observations are confirmed
in vivo, then administration of thrombin or hemoglobin should be carefully timed to coincide
with trough DFO levels.
The limitations of this study are acknowledged. The concentration of hemin (30 µM)
was chosen due to its solubility in MEM10 and its previously-demonstrated toxicity in this
culture system [10, 16, 18]. However, the use of alternative hemin concentrations and media
may influence results in other models. The optimal hemin concentration and culture conditions
must be empirically determined for each system. The highly controlled in vitro environment
facilitates mechanistic investigation at the cellular and molecular level, but it cannot replicate
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many aspects of the complex and evolving cellular microenvironment within an intracerebral
hematoma and surrounding tissue. Multiple factors that are absent in vitro may modify the
cellular response to hemoglobin, hemin and thrombin, as well as the local availability of
exogenous and endogenous iron chelators. While the present results are consistent with the
hypothesis that iron chelators antagonize the protective effect of thrombin and methemoglobin
preconditioning, further testing in appropriate in vivo models is warranted.
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Figure Legends
Fig. 1. Iron chelators reduce ferritin induction by methemoglobin. Bars represent mean HO-1
(A) or ferritin (B) band densities in lysates of cultures (5/condition) treated with 3 µM
methemoglobin (MetHb) for 24 hours, alone or with 100 µM of either deferoxamine (DFO) or
2.2’-bipyridyl (BP), expressed as a multiple of the mean value in control cultures subjected to
sham medium changes only (= 1). Lane order of representative immunoblots is same as bar
order; actin is gel-loading control. ***P < 0.001 v. sham controls, #P < 0.05, ##P < 0.01 v.
metHb alone condition.

Fig. 2. Iron chelators prevent ferritin induction by thrombin. Cultures (5/condition) were treated
with 5 units/ml thrombin for 24 hours alone or with 100 µM deferoxamine (DFO) or 2.2’bipyridyl (BP). Bars represent mean HO-1 (a) or ferritin (b) band densities, scaled to the mean
value in control cultures subjected to sham medium exchange only (= 1).

Lane order of

representative immunoblots is same as bar order; actin is gel-loading control. *P < 0.05, **P <
0.01, ***P < 0.001 v. sham controls, ##P < 0.01 v. thrombin alone condition.

Fig. 3. Methemoglobin and thrombin preconditioning reduce the cytosolic labile iron increase
after hemin treatment; chelators reverse this effect. Phase contrast (a,c) and fluorescence (b, d-h)
photomicrographs of cortical glial cultures stained with calcein AM after: a,b) control medium
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exchanges only; culture monolayer is intact with bright calcein fluorescence; c,d) sham
pretreatment (MEM10) for 24 h followed by hemin 30 µM for 3 h, showing intact culture
monolayer but calcein fluorescence quenching, indicating increased cytosolic labile iron; e) same
culture as in c, d, after adding cell-permeable iron chelator 1,10-phenanthroline, which reverses
calcein fluorescence quenching, demonstrating membrane integrity and ability to retain calcein;
f) culture pretreated with 3 µM methemoglobin for 24 h, then 30 µM hemin for 3 hours; g,h)
cultures pretreated with 3 µM methemoglobin plus 100 µM deferoxamine (g) or 100 µM 2,2bipyridyl (h) for 24 h, then hemin 30 µM for 3 hours; preconditioning effect is reduced. Scale
bar = 100 µm. Bars represent mean calcein fluorescence intensity in cultures pretreated for 24
hours with MEM10 medium only, 3 µM methemoglobin (Met, i), or 5 units/ml thrombin (Thr, j),
alone or with 100 µM deferoxamine (DFO) or 2.2’-bipyridyl (BP), then washed and treated with
30 µM hemin without chelators for 3 hours. Calcein fluorescence values are normalized to that
in control cultures exposed to MEM10 medium only (= 100). ***P < 0.001 v. fluorescence in
cultures pretreated with methemoglobin or thrombin alone and then treated with hemin, ###P <
0.001 v. that in control cultures treated with MEM10 medium only.

Fig 4. Protective effect of methemoglobin and thrombin preconditioning is attenuated by iron
chelators. Phase contrast photomicrographs of glial cultures treated with: a) medium exchanges
only; b-d) hemin 30 µM for 8 h, after pretreatment for 24 hours with MEM10 medium only (b),
metHb 3 µM (c), or metHb 3 µM plus 2,2’-bipyridyl 100 µM (d). Scale bar = 100 µm. Bars
represent mean medium LDH in cultures pretreated for 24 h with 3 µM methemoglobin (Met, e)
or 5 units/ml thrombin (Thr, f) alone or with 100 µM deferoxamine (DFO) or 100 µM 2,2’bipyridyl (BP); other cultures were incubated with MEM10 medium only.

After medium

exchange, cultures were then treated with 30 µM hemin for 8 or 24 hours, without chelators.
LDH values are scaled to the mean value in cultures from the same plating treated with 0.1%
Triton X-100 (=100), which lyses all cells. The weak signal in control cultures subjected to
medium exchange only was subtracted from all values to yield the LDH activity associated with
neurotoxicity.

**P < 0.01, ***P < 0.001 v. mean value in cultures pretreated with

methemoglobin or thrombin alone, #P<0.05, ###P < 0.001 v. value in cultures pretreated with
MEM10 medium alone, n = 14-18/condition.
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Fig. 5. Decreasing the duration of chelator therapy preserves the cytoprotective effect of metHb
and thrombin preconditioning. Cultures were pretreated for 24 h with 3 µM methemoglobin
(Met, a) or 5 units/ml thrombin (Thr, b) as in Fig. 4, but 100 µM DFO was present only for the
first 11 hours of the preconditioning interval. After medium exchange, cultures were then treated
with 30 µM hemin for 8 or 24 hours, without DFO. Medium LDH values are scaled to the mean
value in cultures treated with 0.1% Triton X-100 (=100), which lyses all cells. The weak signal
in control cultures subjected to medium exchange only was subtracted from all values to yield
the LDH activity associated with neurotoxicity. ###P < 0.001 v. value in control cultures
incubated in MEM10 medium alone, n = 14-18/condition.
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